Released Mar 30, 2021, before the open
10-K filed Mar 30, 2021, 89 days after period end · 0001558370-21-003681
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$19.50M$19.50M derived+9.8% vs Q4 2019+80.7% vs Q3 2020
Net Income$397.00K$397.00K derived+36.4% vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$2,839,000+29.0%
Operating Cash Flowderived-$7,550,000N/M
Free Cash Flowderived-$7,825,000N/M
Margins · derived
Operating margin14.6%+2.2 pt vs Q4 2019
Net margin2.0%+0.4 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | $19.50M | $17.76M | $27.02M | $4.31M |
| Net Income | $397.00K | $291.00K | -$5.43M | -$13.31M |
| EPS Diluted | — | $0.02 | -$0.40 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR